To date, an alternative strategy in preventing the progression of ER-dependent breast tumors is represented by drugs that inhibit the aromatase enzyme and interfere with the biosynthesis of estrogens, leading to a drastic reduction of circulating estrogen levels (5). The gene discussed is ESR1; the disease is breast neoplasm.